NCT05504642撤回2 期
Nivolumab and Ipilimumab for Chemo-radio-immunotherapy Followed by Maintenance Therapy With Nivolumab and Ipilimumab for Primary Treatment in Locally Advanced Cervical Cancer Patients
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 撤回
- 主要终点
- Progression free survival (PFS)
研究概览
简要总结
The purpose of this study is to use Chemo-radio-immunotherapy and maintenance therapy with Nivolumab and Ipilimumab in order to achieve improved outcome in patients with locally advanced cervical cancer.
详细描述
After being informed about the study and potential risks, all eligible patients giving written informed consent will undergo a Pre-Chemo-radio-immunotherapy Treatment with Nivolumab and Ipilimumab for 2 weeks. In the following week 1-7, concurrent Chemo-radio-Immunotherapy will consist of standard administration of concurrent Cisplatin mono during radiotherapy, with simultaneous application of Nivolumab and Ipilimumab according to trial protocol. This is followed by Maintenance Treatment for 6 months with Nivolumab and Ipilimumab according to trial protocol.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- Female
- 接受健康志愿者
- 否
入选标准
- •Fully-informed written consent.
- •Females ≥ 18 years of age
- •Histologically confirmed squamous cell, adeno- adenosquamous carcinoma of the cervix uteri. Surgical staging prior to treatement is optional.
- •FIGO stage ≥ IIB and/or histologically confirmed pelvic lymph node metastases.
- •Eastern Cooperative Oncology Group (ECOG) performance status ≤
- •Adequate bone marrow, hepatic and renal function including the following:
- •Haemoglobin ≥ 9.0 g/dL, absolute neutrophil count ≥ 1,500 /µL, platelets ≥100,000 /µL;
- •Total bilirubin ≤ 1.5 x upper normal limit; (except subjects with Gilbert Syndrome who can have total bilirubin < 3.0 mg/dL);
- •AST (SGOT), ALT (SGPT) ≤ 3 x upper normal limit;
- •International normalized ratio (INR) ≤ 1.25;
- •Creatinine ≤ 1.5 x upper normal limit OR measured or calculated creatinine clearance (according to Cockcroft-Gault) ≥40 mL/min for participant with creatinine levels >1.5 × institutional ULN (GFR can also be used in place of creatinine or CrCl)
- •Female patients with reproductive potential must have a negative urine or serum pregnancy test within 7 days prior to start of trial. Women must not be breastfeeding.
- •The patient is willing and able to comply with the protocol for the duration of the study, including hospital visits for treatment and scheduled follow-up visits and examinations.
- •WOCBP must agree to follow instructions for method(s) of contraception for the treatment time and 5 months after.
排除标准
- •Previous systemic therapy in the first-line setting.
- •Patients with neuroendocrine (small cell or large cell) tumors or mixed neuroendocrine histology.
- •Patients with histologically confirmed para-aortic lymph node metastases.
- •Prior organ allograft or allogeneic bone marrow transplantation.
- •Local therapies ongoing or completed <4 weeks prior to the baseline scan.
- •Thrombotic or embolic events such as cerebrovascular accident (including transient ischemic attacks), deep vein thrombosis or pulmonary embolism within the 6 months prior to the first dose of study drug with the exception of thrombosis of a segmental portal vein.
- •Prior, systemic anti-cancer chemotherapy, radiotherapy administered <4 weeks prior to study entry, endocrine- or immunotherapy or use of other investigational agents.
- •Major surgery within 4 weeks of starting the study. Patients must have recovered from effects of major surgery.
- •Malignancies other than disease under study within 5 years prior to inclusion, with the exception of those with a negligible risk of metastasis or death (e.g., expected 5-year OS rate >90%) treated with expected curative outcome (such as adequately treated carcinoma in situ of the cervix, basal or squamous cell skin cancer, localized prostate cancer treated surgically with curative intent, ductal carcinoma in situ treated surgically with curative intent)
- •Any serious or uncontrolled medical disorder or active infection that, in the opinion of the investigator, may increase the risk associated with study participation, study drug administration, or would impair the ability of the subject to receive study drug.
- •Psychiatric disorders or altered mental status precluding understanding of the informed consent process and/or compliance with the study protocol.
- •Subjects with a history of or current CNS metastases. A scan to confirm the absence of brain metastases is not required. Patients with unknown CNS metastatic status and any clinical signs indicative of CNS metastases are eligible if CNS metastases are excluded using CT and/or MRI scans.
- •Pregnant or breast-feeding women.
- •Any positive test result for hepatitis B virus (e.g. surface antigen [HBV sAg, Australia antigen] positive) or hepatitis C virus (Hepatic C antibody [anti-HCV] positive, except if HCV-RNA negative.
- •Immunocompromised patients, e.g. patients with positive testing for HIV at screening visit or those under corticoid medication or immunosuppressive drugs (e.g. methotrexate).
- •Subjects with active, known, or suspected autoimmune disease. Subjects with Type I diabetes mellitus, residual hypothyroidism due to autoimmune thyroiditis only requiring hormone replacement, or skin disorders (such as vitiligo, psoriasis, or alopecia) not requiring systemic treatment are permitted to enroll. For any cases of uncertainty, it is recommended that the coordinating investigator be consulted prior to signing informed consent.
- •Subjects with a condition requiring systemic treatment with either corticosteroids (> 10 mg daily prednisone equivalents) or other immunosuppressive medications within 14 days prior to study drug administration. Inhaled or topical steroids, and adrenal replacement doses > 10 mg daily prednisone equivalents are permitted in the absence of active autoimmune disease.
- •Prior treatment with an anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CD137, or anti-CTLA-4 antibody, or any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways.
- •Non-resolved (> Grade 1 (NCI CTCAE version 5) toxicities attributed to prior anti-cancer therapy other than hearing loss, alopecia and fatigue
- •> Grade 1 peripheral neuropathy according to CTCAE version
- •History of allergy or hypersensitivity to study drugs or any constituent of the products
- •Patient is currently participating in or has participated in a study of an investigational agent or has used an investigational device within 4 weeks prior to the first dose of study treatment.23.Patient who has been incarcerated or involuntarily institutionalized by court order or by the authorities § 40 Abs. 1 S. 3 Nr. 4 AMG.24.Patients who are unable to consent because they do not understand the nature, significance and implications of the clinical trial and therefore cannot form a rational intention in the light of the facts [§ 40 Abs. 1 S. 3 Nr. 3a AMG].
研究组 & 干预措施
Study medication
Experimental
All eligible patients will receive study medication:
- Pre-Chemo-radio-immunotherapy Treatment for two weeks before start of Chemo-radio-immunotherapy
- Concurrent Chemo-radio-immunotherapy (week 1-7)
- Maintenance Treatment (six months) after Chemo-radio-immunotherapy
干预措施: Pre-Chemo-radio-immunotherapy Treatment (Nivolumab/Ipilimumab) (Drug)
Study medication
Experimental
All eligible patients will receive study medication:
- Pre-Chemo-radio-immunotherapy Treatment for two weeks before start of Chemo-radio-immunotherapy
- Concurrent Chemo-radio-immunotherapy (week 1-7)
- Maintenance Treatment (six months) after Chemo-radio-immunotherapy
干预措施: Concurrent Chemo-radio-immunotherapy (Nivolumab/Ipilimumab) (Drug)
Study medication
Experimental
All eligible patients will receive study medication:
- Pre-Chemo-radio-immunotherapy Treatment for two weeks before start of Chemo-radio-immunotherapy
- Concurrent Chemo-radio-immunotherapy (week 1-7)
- Maintenance Treatment (six months) after Chemo-radio-immunotherapy
干预措施: Maintenance Treatment (Nivolumab/Ipilimumab) (Procedure)
结局指标
主要结局
Progression free survival (PFS)
时间窗: From Baseline to 2 years
Tumor response assessed by MRI Pelvic according to resist
The adverse events according to NCI-CTCAE v5.0
时间窗: From the time of signed informed consent until 100 days after the last study drug administration
Safety and tolerability (according to NCI-CTCAE v5.0)
次要结局
未报告次要终点
研究者
相似试验
进行中（未招募）
1 期
Does adding double immunotherapy to the combination of chemotherapy and radiotherapy result in a better anti-tumor efficacy?locally advanced non-small cell lung cancerMedDRA version: 21.1Level: PTClassification code 10061873Term: Non-small cell lung cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.1Level: PTClassification code 10029519Term: Non-small cell lung cancer stage IIISystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2019-003454-83-NLAmsterdam UMC, VU University Medical Center29
已完成
2 期
Ipilimumab plus Nivolumab and ChemoRadiotherapy followed by Surgery in patients with resectable and borderline resectable T3-4N0-1 NSCLClung carcinoma1003866610029107lung cancerNL-OMON48462Vrije Universiteit Medisch Centrum29
招募中
不适用
Ipilimumab plus nivolumab and chemoradiotherapy followed by surgery in patients with resectable and borderline resectable T3-4N0-1 non-small cell lung cancer(borderline) resectable non-small cell lung cancer (NSCLC), T3-4N0-1NL-OMON24908VU University Medical Center29
进行中（未招募）
2 期
Nivolumab + Ipilimumab + Radiation in MSS Pancreatic CancerMetastatic Pancreatic CancerPancreatic CancerNCT04361162Massachusetts General Hospital30
进行中（未招募）
2 期
Nivolumab+Ipilimumab+RT in MSS mCRCMetastatic Microsatellite Stable Colorectal CancerNCT04575922Massachusetts General Hospital32